SPOTLIGHT -
Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhD
The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]
